CVC Credit has extended its stake in Curium, the Paris‑based nuclear‑medicine firm, with a new debt‑and‑equity package that refines the company’s capital structure. The deal follows a six‑year partnership that began in 2020 when CVC first underwrote Curium alongside sponsor CapVest. By staying on the sidelines, CVC keeps a lead in the latest round for its future growth and expansion.

Curium supplies radiopharmaceuticals that flag cancer and diagnose heart, brain, lung, and bone ailments. The company serves over 6,000 long‑term customers in more than 70 countries, reaching approximately 14 million patients annually. CVC’s Capital Solutions strategy deploys bespoke junior equity or structured debt to fund mergers, refinancings, and liquidity events for high‑quality European sponsors and growth in the global healthcare.

Miguel Toney, partner in CVC Credit’s private‑credit team, praised the partnership, noting that Curium’s leadership in nuclear medicine strengthens the sector’s future. Andrew Davies highlighted the firm’s integrated network, saying it positions CVC to unlock attractive opportunities in resilient businesses that need tailored financing. The transaction solidifies CVC’s foothold amid tightening leveraged‑finance markets for strategic investors seeking growth in healthcare today.